CLINICAL TRIALS PROFILE FOR SULINDAC
✉ Email this page to a colleague
All Clinical Trials for SULINDAC
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003365 ↗ | Sulindac and Plant Compounds in Preventing Colon Cancer | Terminated | National Cancer Institute (NCI) | N/A | 1996-08-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of sulindac may be an effective way to prevent colon cancer. Eating a diet rich in fruits and vegetables appears to reduce the risk of some types of cancer. Curcumin, rutin, and quercetin are compounds found in plants that may prevent the development of colon cancer. PURPOSE: Randomized clinical trial to study the effectiveness of sulindac, curcumin, rutin, and quercetin in preventing colon cancer. |
| NCT00003365 ↗ | Sulindac and Plant Compounds in Preventing Colon Cancer | Terminated | University of Medicine and Dentistry of New Jersey | N/A | 1996-08-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of sulindac may be an effective way to prevent colon cancer. Eating a diet rich in fruits and vegetables appears to reduce the risk of some types of cancer. Curcumin, rutin, and quercetin are compounds found in plants that may prevent the development of colon cancer. PURPOSE: Randomized clinical trial to study the effectiveness of sulindac, curcumin, rutin, and quercetin in preventing colon cancer. |
| NCT00005882 ↗ | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Completed | Chao Family Comprehensive Cancer Center | Phase 3 | 1998-07-01 | This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer |
| NCT00005882 ↗ | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Completed | National Cancer Institute (NCI) | Phase 3 | 1998-07-01 | This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer |
| NCT00005882 ↗ | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Completed | University of California, Irvine | Phase 3 | 1998-07-01 | This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer |
| NCT00037609 ↗ | Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients | Completed | Cell Pathways | Phase 1/Phase 2 | 2001-01-01 | The primary objective of the phase I study is to determine a safe dose for combination therapy with capecitabine and exisulind. A secondary objective is to assess pharmacokinetic interactions between the two drugs and assess the biological activity of exisulind. The primary objective of the Phase II part of this study is to assess the anti-tumor activity of this combination therapy measured by objective tumor response. Secondary end points also assessed will be toxicity of therapy, duration of response and time to progression. |
| NCT00037609 ↗ | Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients | Completed | M.D. Anderson Cancer Center | Phase 1/Phase 2 | 2001-01-01 | The primary objective of the phase I study is to determine a safe dose for combination therapy with capecitabine and exisulind. A secondary objective is to assess pharmacokinetic interactions between the two drugs and assess the biological activity of exisulind. The primary objective of the Phase II part of this study is to assess the anti-tumor activity of this combination therapy measured by objective tumor response. Secondary end points also assessed will be toxicity of therapy, duration of response and time to progression. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SULINDAC
Condition Name
Clinical Trial Locations for SULINDAC
Trials by Country
Clinical Trial Progress for SULINDAC
Clinical Trial Phase
Clinical Trial Sponsors for SULINDAC
Sponsor Name
